Pricing Log in Create free account
Saturday 7 November 2026 Export GOVX’s income statement to Excel — free account

GeoVax Labs Inc.

GOVX Healthcare Biotechnology

GeoVax Labs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 million, down 37.1% from fiscal 2024.

Revenue
+183.4%
EPS
+88.9%
Free cash flow
+15.8%

Quarter to June 2026, against a year earlier

0.15 0.01 −6.25%
Market cap
$1.6M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
n/a
Altman Z
−42.55
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 1.60
Revenue ttm 6.14
Net income ttm (20.43)
Free cash flow ttm (18.37)
Net debt Q (3.14)
Valuation
P/E 0.00
Forward P/E (0.03) (negative: loss-making)
Price / sales 0.11
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.39
Financial health
Current ratio Q 1.54 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (591.80)
Growth
Revenue growth Q +183.44% (above 0%: growing)
Operating income growth Q +18.03% (above 0%: growing)
EPS, this year +77.05% (at or above 15%: strong)
EPS, next year A +48.64% (at or above 15%: strong)
Revenue, next year A −67.34% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +49.07% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of 1.1×; over the ten years it ranged from −55.8× in 2022 to 68,586,623,689× in 2016.
P/S against its own 10 years 0.04%
10-year low 10-year high
P/B against its own 10 years 6.01%
10-year low 10-year high
EV/FCF against its own 10 years 22.11%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 6 6 3 3
Receivables — 1 — —
Inventory — — — —
Other — — — —
8 8 5 4
2023 2024 2025 Q'26
Payables 3 2 1 2
ST’ Debt — — — —
Other — — — —
4 3 2 3

Compound Annual Growth %

10y 5y 3y
Sales 10.92% 16.18% 86.21%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 12.25% (16.76%) (47.61%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −2.16 Actual −0.97

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY25 −10.25 −8.75 Beat by 1.50
Q3 FY25 −6.00 −7.75 Miss by 1.75
Q1 FY26 −1.60 −2.62 Miss by 1.02
Q2 FY26 −2.16 −0.97 Beat by 1.19
Q3 FY26 −1.03 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (2.62) (0.97) — — —
’25 (11.25) (8.75) (7.75) (2.29) (22.40)
’24 (61.75) (49.75) (22.75) (21.89) (120.50)
’23 (56.22) (82.46) (119.94) (87.04) (357.25)
’22 (127.44) (67.47) (63.72) (74.96) (311.09)
’21 (108.70) (78.71) (116.19) (839.58) (1.14k)
’20 (974.51) (224.89) (273.61) 673.14 (802.10)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 2 1 — — 2
’24 — 0 3 1 4
’22 0 — — — 0
’21 0 0 0 0 0
’20 1 0 0 0 2
’19 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (6) (4) (6) (5) (21)
’24 (6) (2) (9) (8) (25)
’23 (4) (6) (5) (10) (25)
’22 (4) (4) (4) (7) (19)
’21 (2) (1) (2) (7) (11)
’20 0 (1) 0 (2) (3)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (6) (4) (6) (5) (22)
’24 (6) (2) (9) (8) (25)
’23 (4) (6) (5) (10) (25)
’22 (4) (4) (4) (7) (19)
’21 (2) (1) (2) (7) (11)
’20 0 (1) 0 (2) (3)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 1 1 1 2 0 0 — 4 2 6 +13.0% — — — —
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — 100.00 100.00 100.00 0.0 pt
EBT (3) (2) (3) (2) (3) (19) (14) (26) (25) (21) (20) +23.2%
EBT margin, % (394.70) (201.82) (265.79) (201.60) (162.20) (4,817.20) (17,203.80) 0.00 (631.98) (862.35) 0.00 (467.6) pt
Net income (3) (2) (3) (2) (3) (19) (14) (26) (25) (21) (20) +23.2%
Per share, $
Per share, $ Revenue 0.02 0.02 0.00 0.00 492.89 23.65 1.80 0.00 19.10 2.60 0.00 +71.7%
Earnings (0.08) (0.03) (149,925,000.00) (294,227.90) (802.10) (1,139.43) (311.09) (357.25) (120.50) (22.40) (13.63) +87.3%
Cash flow (0.05) (0.02) 0.00 0.00 (743.41) (686.90) (420.09) (346.27) (119.21) (22.42) (4.02) +98.5%
Capex 0.00 0.00 0.00 0.00 (42.38) (2.93) (2.96) (0.67) (0.10) (0.03) 0.00 n/m
Free cash flow (0.05) (0.02) 0.00 0.00 (785.78) (689.82) (423.06) (346.94) (119.31) (22.44) (4.02) +98.5%
Book value 0.01 0.00 0.00 0.00 2,586.19 267.59 587.20 79.28 24.39 3.99 0.39 +106.7%
Shares, m 42 69 0 0 0 0 0 0 0 1 2 (34.2%)
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.0
P/S 31,053,854,505.97 37,008,444,940.48 0.00 0.00 2.57 57.40 29.93 — 3.17 0.67 0.11 7,562,477,726.7
P/B 0.00 0.00 0.00 0.00 0.49 5.07 0.40 — 2.53 1.07 0.39 1.1
EV/Sales 31,053,854,505.42 37,008,444,940.19 (0.23) (0.21) (2.60) 28.92 (46.25) — 1.91 0.24 (0.33) 7,562,477,714.2
EV/FCF (13,119,541,284.17) (23,504,920,550.35) 0.14 0.17 1.63 (0.98) 0.86 — (0.31) (0.07) 0.11 (4,069,384,648.1)
Cash, $m
Cash, $m Operating cash flow (2) (2) (2) (1) (3) (11) (19) (25) (25) (21) (18) +30.6%
Capex — 0 — 0 0 0 0 0 0 0 0 +25.8%
Free cash flow (2) (2) (2) (1) (3) (11) (19) (25) (25) (22) (18) +30.6%
Balance, $m
Balance, $m Working capital 0 0 (1) (2) 9 6 24 4 5 3 1 +39.0%
Net debt 0 0 0 0 (10) (11) (28) (6) (6) (3) (3) +23.7%
Shareholders’ equity 0 0 (1) (2) 10 4 27 6 5 4 2 +36.0%
Returns, %
Returns, % ROA (336.98) (394.44) (452.19) (426.75) (54.46) (167.37) (65.00) (127.82) (286.62) (296.11) (408.79) +40.9 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (1,829.11) 0.00 (1,829.1) pt
ROE 1,035.68 144.85 98.20 72.93 (98.84) (268.08) (90.57) (160.47) (462.32) (483.78) (891.59) (1,519.5) pt
People
People Employees 11 9 9 7 9 11 14 17 17 19 — +6.3%
Revenue/emp, $m 0.08 0.12 0.11 0.17 0.20 0.04 0.01 0.00 0.23 0.13 — +6.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2025 · fundamentals updated 26 Oct 2026

GeoVax Labs Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GNPX GENPREX $1.7M — (loss-making) — — n/m −32.98% (below 0%: shrinking) 0.00% 0.00% Compare
PPCB Propanc Biopharma Inc $1.7M — (loss-making) — — −99.64% (below 0%: shrinking) −1,637.42% (below 0%: shrinking) — 0.00% Compare
XRTX XORTX Therapeutics Inc. $1.7M — (loss-making) — — n/m −318.40% (below 0%: shrinking) 0.00% 0.00% Compare
GOVX GeoVax Labs Inc. $1.6M — (loss-making) — (loss-making) +183.44% (above 0%: growing) n/m +15.81% (above 0%: growing) 100.00% 0.00%
ITRMF Iterum Therapeutics PLC $1.6M — (loss-making) — (loss-making) +110.81% (above 0%: growing) n/m −179.15% (below 0%: shrinking) 94.87% (1,982.31%) Compare
OGEN Oragenics, Inc. $1.6M — (loss-making) — (loss-making) −75.33% (below 0%: shrinking) n/m −66.37% (below 0%: shrinking) 100.00% 0.00% Compare
VRAX Virax Biolabs Group Limited $1.6M — (loss-making) — (loss-making) — −855.56% (below 0%: shrinking) +32.24% (above 0%: growing) (53.57%) 0.00% Compare
KAPA Kairos Pharma, Ltd. $1.5M — (loss-making) — — n/m −25.71% (below 0%: shrinking) — 0.00% Compare
CARM Carisma Therapeutics Inc. $1.5M — (loss-making) — (loss-making) +392.01% (above 0%: growing) n/m +114.65% (above 0%: growing) 100.00% 96.83% Compare
Median of peers $1.6M — — +110.81% — −49.67% 47.44% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 10 September 2026

Ownership

Directors and executive officers, together less than 1%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

GeoVax Labs Inc. (GOVX) Latest News

27 Oct

Impact 4 · · NewMediaWire

26 Oct

Impact 4 ·

6 Oct

Impact 4 · · NewMediaWire

29 Sep

Impact 4 · · NewMediaWire

21 Sep

Impact 4 · · NewMediaWire

16 Sep

Impact 3 ·

14 Sep

Impact 3 ·

9 Sep

Impact 4 ·

25 Aug

Impact 4 ·

24 Aug

Impact 4 ·
Impact 3 ·

13 Aug

Impact 3 ·

11 Aug

Impact 3 ·

10 Aug

Impact 4 ·

6 Aug

Impact 4 ·

21 Jul

Impact 4 ·

1 Jul

Impact 4 ·

27 Jun

Impact 4 ·

17 Jun

Impact 4 ·

8 Jun

Impact 3 · · NewMediaWire

3 Jun

Impact 3 · · NewMediaWire

26 May

Impact 4 · · NewMediaWire
Impact 3 · · Simply Wall St.

20 May

Impact 3 · · NewMediaWire

18 May

Impact 3 · · NewMediaWire
Impact 3 · · NewMediaWire

15 May

Impact 4 · · Zacks

14 May

Impact 4 · · NewMediaWire

13 May

Impact 3 · · NewMediaWire

7 May

Impact 3 · · NewMediaWire
stockrow.com/GOVX · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com